MX2020013614A - Métodos y composiciones para tratar y/o prevenir el progreso y/o inicio de neurodegeneración relacionada con la edad. - Google Patents
Métodos y composiciones para tratar y/o prevenir el progreso y/o inicio de neurodegeneración relacionada con la edad.Info
- Publication number
- MX2020013614A MX2020013614A MX2020013614A MX2020013614A MX2020013614A MX 2020013614 A MX2020013614 A MX 2020013614A MX 2020013614 A MX2020013614 A MX 2020013614A MX 2020013614 A MX2020013614 A MX 2020013614A MX 2020013614 A MX2020013614 A MX 2020013614A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- onset
- age
- treating
- preventing
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- WUJVPODXELZABP-FWJXURDUSA-N trodusquemine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCNCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 WUJVPODXELZABP-FWJXURDUSA-N 0.000 abstract 2
- 230000032683 aging Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684496P | 2018-06-13 | 2018-06-13 | |
| PCT/US2019/036946 WO2019241503A1 (en) | 2018-06-13 | 2019-06-13 | Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013614A true MX2020013614A (es) | 2021-05-27 |
Family
ID=68838925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013614A MX2020013614A (es) | 2018-06-13 | 2019-06-13 | Métodos y composiciones para tratar y/o prevenir el progreso y/o inicio de neurodegeneración relacionada con la edad. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190381071A1 (https=) |
| EP (1) | EP3806862A4 (https=) |
| JP (1) | JP2021527090A (https=) |
| KR (1) | KR20210009422A (https=) |
| CN (1) | CN112566641A (https=) |
| AU (1) | AU2019285065A1 (https=) |
| BR (1) | BR112020025296A2 (https=) |
| CA (1) | CA3103463A1 (https=) |
| MX (1) | MX2020013614A (https=) |
| SG (1) | SG11202012343TA (https=) |
| WO (1) | WO2019241503A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11464789B2 (en) | 2018-08-03 | 2022-10-11 | Enterin, Inc. | Aminosterol compositions and methods of using the same for treating schizophrenia |
| EP3829587A4 (en) * | 2018-08-03 | 2022-07-20 | Enterin, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN AND GUESS DISORDERS |
| WO2020028791A1 (en) * | 2018-08-03 | 2020-02-06 | Enterin Laboratories | Low dosage intranasal aminosterol dosage forms and methods of using the same |
| CN110827282B (zh) * | 2020-01-13 | 2020-04-10 | 南京慧脑云计算有限公司 | 一种基于磁共振成像的脑白质纤维束示踪分析方法及系统 |
| CN111110873A (zh) * | 2020-02-24 | 2020-05-08 | 苏州欣影生物医药技术有限公司 | 一种磁共振/核医学双模态分子影像探针的制备方法 |
| CN111528839B (zh) * | 2020-05-29 | 2023-06-23 | 北京京东方健康科技有限公司 | 睡眠检测方法和装置、助眠设备和方法 |
| WO2022244929A1 (ko) * | 2021-05-21 | 2022-11-24 | 애니머스큐어 주식회사 | 이노토디올을 포함하는 근육 질환의 예방 또는 치료용 조성물 |
| WO2025054408A1 (en) * | 2023-09-07 | 2025-03-13 | NeuroTherapia, Inc. | Methods of treating cognitive impairment |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143738A (en) * | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
| JP2010538072A (ja) * | 2007-09-06 | 2010-12-09 | ジェナエラ コーポレイション | 糖尿病を治療する方法 |
| WO2011066260A2 (en) * | 2009-11-25 | 2011-06-03 | Michael Zasloff | Formulations comprising aminosterols |
| US10040817B2 (en) * | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
-
2019
- 2019-06-13 AU AU2019285065A patent/AU2019285065A1/en not_active Abandoned
- 2019-06-13 US US16/440,414 patent/US20190381071A1/en not_active Abandoned
- 2019-06-13 EP EP19818961.5A patent/EP3806862A4/en not_active Withdrawn
- 2019-06-13 CN CN201980052151.2A patent/CN112566641A/zh active Pending
- 2019-06-13 US US17/251,322 patent/US20210252023A1/en not_active Abandoned
- 2019-06-13 MX MX2020013614A patent/MX2020013614A/es unknown
- 2019-06-13 CA CA3103463A patent/CA3103463A1/en active Pending
- 2019-06-13 JP JP2020569002A patent/JP2021527090A/ja active Pending
- 2019-06-13 WO PCT/US2019/036946 patent/WO2019241503A1/en not_active Ceased
- 2019-06-13 SG SG11202012343TA patent/SG11202012343TA/en unknown
- 2019-06-13 KR KR1020217000559A patent/KR20210009422A/ko not_active Ceased
- 2019-06-13 BR BR112020025296-4A patent/BR112020025296A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019241503A1 (en) | 2019-12-19 |
| CN112566641A (zh) | 2021-03-26 |
| BR112020025296A2 (pt) | 2021-03-09 |
| JP2021527090A (ja) | 2021-10-11 |
| US20210252023A1 (en) | 2021-08-19 |
| EP3806862A4 (en) | 2022-07-06 |
| SG11202012343TA (en) | 2021-01-28 |
| EP3806862A1 (en) | 2021-04-21 |
| US20190381071A1 (en) | 2019-12-19 |
| KR20210009422A (ko) | 2021-01-26 |
| AU2019285065A1 (en) | 2021-01-07 |
| CA3103463A1 (en) | 2019-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013614A (es) | Métodos y composiciones para tratar y/o prevenir el progreso y/o inicio de neurodegeneración relacionada con la edad. | |
| IL286636A (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS | |
| PH12020551208A1 (en) | Compounds for the treatment of kinase-dependent disorders | |
| IL285782A (en) | Compounds, compositions, and methods for treating disease | |
| MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| EP4365179A3 (en) | Novel rapamycin derivatives | |
| MY208545A (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
| SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
| JOP20180094A1 (ar) | مركب حلقي غير متجانس كمثبط بروتين كيناز | |
| SG11202107325TA (en) | Methods and compositions for the treatment of fabry disease | |
| IL279210A (en) | Topical ingredients to stimulate hair growth | |
| SG10201907289VA (en) | Monomethylfumarate prodrug compositions | |
| WO2020055643A3 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| SA522431538B1 (ar) | طُرق وتركيبات لعلاج تساقط الشعر | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| WO2016130460A3 (en) | Phthalazinone pyrazole derivatives for treating retinal degenerative disease | |
| PH12022550497A1 (en) | Perk inhibiting compounds | |
| MX2020010086A (es) | Métodos y composiciones para tratar alucinaciones y afecciones relacionadas con las mismas. | |
| NZ757526A (en) | Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| ZA202211253B (en) | Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases | |
| EP4017873A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH | |
| TW201713630A (en) | Substituted quinazoline compounds and methods of use thereof | |
| NZ780966A (en) | Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof | |
| SG11202105664VA (en) | Methods of promoting healthy catch-up growth |